首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1519530

2024-2032 年癌症疫苗市場報告（按類型、技術、適應症、最終用戶和地區）

Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2024-2032

出版日期: 2024年07月01日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年全球癌症疫苗市場規模達68億美元。癌症發病率的增加、免疫療法的進步、政府的舉措和資助、意識和教育的提高、技術的快速進步、戰略合作和夥伴關係以及醫療保健支出的增加是推動市場的一些主要因素。

癌症疫苗是一種免疫療法，旨在刺激人體免疫系統識別和攻擊癌細胞。這些疫苗透過訓練免疫系統識別特定的癌症相關抗原來發揮作用，這些抗原是在癌細胞上發現的可以觸發免疫反應的物質。透過將這些抗原引入體內，癌症疫苗旨在激活免疫系統針對癌症的天然防禦機制。癌症疫苗主要有兩種類型，即預防性疫苗和治療性疫苗。預防性癌症疫苗用於預防由傳染源引起的某些類型的癌症，例如人類乳突病毒 (HPV) 或乙型肝炎病毒 (HBV)。這些疫苗刺激免疫系統產生對傳染原的免疫反應，降低相關癌症的風險。另一方面，治療性癌症疫苗旨在治療現有的癌症。它們透過引入癌症特異性抗原或增強免疫系統對這些抗原的辨識來增強針對癌細胞的免疫反應。這些疫苗可以個人化，針對個別患者腫瘤細胞中存在的特定抗原。

全球癌症盛行率的上升是癌症疫苗市場的重要驅動力。由於癌症是導致死亡的主要原因，因此對有效的預防和治療干預措施的需求不斷成長。此外，包括癌症疫苗在內的免疫療法已成為腫瘤學中一種有前景的治療方法。新型免疫治療策略的發展和現有免疫療法的成功推動了對癌症疫苗的需求。除此之外，一般民眾對癌症預防和早期發現重要性的認知也不斷提高。教育活動、篩檢計畫和公眾意識措施的增加導致對包括癌症疫苗在內的預防措施的需求更大。除此之外，市場也見證了製藥公司、研究機構和學術機構之間的合作。這些夥伴關係促進了知識、資源和專業知識的交流，從而加速了癌症疫苗的開發和商業化。與此一致的是，不斷成長的醫療保健支出，特別是在新興經濟體，提高了癌症疫苗的可近性和可負擔性。可支配收入的增加、醫療基礎設施的改善和保險覆蓋範圍的擴大正在促進市場的成長。此外，全球各國政府都在積極投資包括疫苗在內的癌症研究和開發，這正在創造積極的市場前景。

癌症疫苗市場趨勢/促進因素：

免疫療法的進展

免疫療法透過利用免疫系統的力量來瞄準和摧毀癌細胞，徹底改變了癌症治療。免疫療法（包括檢查點抑制劑和過繼性細胞療法）的成功為癌症疫苗的開發和採用奠定了堅實的基礎。癌症疫苗刺激針對腫瘤抗原的特異性免疫反應的能力進一步補充了現有的免疫治療策略。這種協同作用刺激了對癌症疫苗作為聯合療法不可或缺的一部分的需求，從而導致其市場成長。

政府措施和資金

世界各國政府已經意識到迫切需要解決日益嚴重的癌症負擔。因此，他們積極投資癌症研究、發展和醫療基礎設施。政府為從事癌症疫苗研發的公司提供財政支持、補助和激勵措施。此外，監管機構正在與疫苗開發商密切合作，以簡化核准流程並促進市場准入。這些支持性政策和融資措施極大地促進了市場的成長，使企業能夠投資於研究、臨床試驗和製造能力。

提高認知和教育

一般民眾對癌症預防和早期檢測的認知不斷提高，對癌症疫苗的需求產生了深遠的影響。公共衛生運動、教育計畫和倡導團體的計劃都強調了疫苗接種作為預防某些癌症的措施的重要性。 HPV 和 HBV 疫苗等癌症相關感染預防性疫苗的成功進一步增強了癌症疫苗的重要性。隨著人們對癌症預防和免疫的好處越來越了解，對癌症疫苗的需求預計將增加，從而推動市場成長。

The global cancer vaccines market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.7 Billion by 2032, exhibiting a growth rate (CAGR) of 10.2% during 2024-2032. The increasing cancer incidence, advancements in immunotherapy, government initiatives and funding, growing awareness and education, rapid technological advancements, strategic collaborations and partnerships, and increasing healthcare expenditure are some of the major factors propelling the market.

Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. These vaccines work by training the immune system to recognize specific cancer-related antigens, substances found on cancer cells that can trigger an immune response. By introducing these antigens into the body, cancer vaccines aim to activate the immune system's natural defense mechanisms against cancer. There are two main types of cancer vaccines, namely preventive (prophylactic) and therapeutic vaccines. Preventive cancer vaccines are used to prevent certain types of cancer caused by infectious agents, such as human papillomavirus (HPV) or hepatitis B virus (HBV). These vaccines stimulate the immune system to produce an immune response against the infectious agent, reducing the risk of developing associated cancers. Therapeutic cancer vaccines, on the other hand, are designed to treat existing cancers. They work by boosting the immune response against cancer cells, either by introducing cancer-specific antigens or by enhancing the immune system's recognition of these antigens. These vaccines can be personalized, targeting specific antigens present in an individual patient's tumor cells.

The rising prevalence of cancer worldwide is a significant driver for the cancer vaccines market. With cancer being a leading cause of mortality, there is a growing demand for effective preventive and therapeutic interventions. Additionally, immunotherapy, including cancer vaccines, has emerged as a promising treatment approach in oncology. The development of novel immunotherapeutic strategies and the success of existing immunotherapies have propelled the demand for cancer vaccines. Other than this, there is a rising awareness among the general population about the importance of cancer prevention and early detection. Increased education campaigns, screening programs, and public awareness initiatives have resulted in a greater demand for preventive measures, including cancer vaccines. Besides this, the market has witnessed collaborations between pharmaceutical companies, research institutes, and academic institutions. These partnerships facilitate the exchange of knowledge, resources, and expertise, leading to accelerated development and commercialization of cancer vaccines. In line with this, the growing healthcare expenditure, particularly in emerging economies, has boosted the accessibility and affordability of cancer vaccines. Rising disposable incomes, improving healthcare infrastructure, and expanding insurance coverage are contributing to market growth. Moreover, governments across the globe are actively investing in cancer research and development, including vaccines, which is creating a positive market outlook.

Cancer Vaccines Market Trends/Drivers:

Advancements in immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and destroy cancer cells. The success of immunotherapeutic approaches, including checkpoint inhibitors and adoptive cell therapies, has created a strong foundation for the development and adoption of cancer vaccines. The ability of cancer vaccines to stimulate a specific immune response against tumor antigens further complements existing immunotherapy strategies. This synergy has fueled the demand for cancer vaccines as an integral part of combination therapies, leading to their market growth.

Government initiatives and funding

Governments worldwide have recognized the urgent need to address the growing burden of cancer. As a result, they are actively investing in cancer research, development, and healthcare infrastructure. Governments provide financial support, grants, and incentives to companies engaged in cancer vaccine research and development. Additionally, regulatory agencies are working closely with vaccine developers to streamline approval processes and facilitate market access. These supportive policies and funding initiatives have significantly contributed to the growth of the market, enabling companies to invest in research, clinical trials, and manufacturing capabilities.

Growing awareness and education

Increased awareness among the general population about cancer prevention and early detection has had a profound impact on the demand for cancer vaccines. Public health campaigns, educational programs, and initiatives by advocacy groups have emphasized the importance of vaccinations as a preventive measure against certain cancers. The success of preventive vaccines for infections linked to cancer, such as HPV and HBV vaccines, has further reinforced the significance of cancer vaccines. As people become more knowledgeable about the benefits of cancer prevention and immunization, the demand for cancer vaccines is expected to increase, thus driving market growth.

Cancer Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global cancer vaccines market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, technology, indication and end user.

Breakup by Type:

Preventive Cancer Vaccines

Therapeutic Cancer Vaccines

Preventive cancer vaccines dominate the market

The report has provided a detailed breakup and analysis of the market based on the type. This includes preventive cancer vaccines and therapeutic cancer vaccines. According to the report, preventive cancer vaccines represented the largest segment.

Preventive cancer vaccines have demonstrated significant success in reducing the incidence of specific cancers associated with infectious agents. Vaccines, such as the human papillomavirus (HPV) and hepatitis B virus (HBV), have proven effective in preventing cervical, anal, and certain types of liver cancer, respectively. The efficacy and safety of these vaccines have led to their widespread acceptance. Additionally, these vaccines offer a proactive approach to cancer prevention. They target specific infectious agents known to contribute to the development of certain cancers, thereby providing a direct means of prevention. This approach is especially appealing as it focuses on reducing the risk of developing cancer in the first place, rather than solely relying on early detection or treatment interventions. As public awareness of the benefits of preventive measures increases, individuals and healthcare providers are embracing the use of preventive cancer vaccines, thus contributing to the segment's market dominance. Other than this, preventive cancer vaccines align with global efforts to reduce the burden of cancer. Moreover, governments and healthcare organizations across the world have recognized the value of prevention in combating cancer and have implemented vaccination programs as part of their public health initiatives. These programs target specific populations, such as adolescents for HPV vaccination, to maximize the preventive impact. The extensive implementation of national immunization programs and the inclusion of preventive cancer vaccines in routine vaccination schedules further drive the market segment.

Breakup by Technology:

Dendritic Cells Cancer Vaccines

Recombinant Cancer Vaccines

Antigen/Adjuvant Cancer Vaccines

Viral Vector and DNA Cancer Vaccines

Whole-cell Cancer Vaccines

Recombinant cancer vaccines hold the largest share in the market

A detailed breakup and analysis of the market based on technology has also been provided in the report. This includes dendritic cells cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, viral vector and DNA cancer vaccines, and whole-cell cancer vaccines. According to the report, recombinant cancer vaccines accounted for the largest market share.

Recombinant technology allows for precise and controlled production of cancer vaccines. These vaccines are developed by inserting specific genes or DNA sequences encoding tumor antigens into a vector such as a virus or bacteria. This genetic engineering technique enables researchers to create vaccines that express tumor-specific antigens, effectively targeting cancer cells while minimizing potential side effects. The ability to tailor the vaccine's composition and antigen profile to match the specific characteristics of a patient's tumor makes recombinant cancer vaccines highly customizable and attractive in personalized medicine approaches. Additionally, recombinant vaccines have demonstrated favorable safety and efficacy profiles. The use of recombinant technology allows for the production of vaccines without using live or attenuated pathogens, reducing the risk of adverse events. Additionally, recombinant vaccines can induce a robust immune response by presenting tumor-specific antigens to the immune system in a controlled manner. This targeted immune response enhances the vaccine's efficacy in recognizing and attacking cancer cells. Other than this, this technology offers scalability and cost-effectiveness in vaccine production. The use of recombinant techniques allows for efficient large-scale production of vaccines, thus meeting the demand for widespread vaccination programs.

Breakup by Indication:

Cervical Cancer

Prostate Cancer

Others

The report has provided a detailed breakup and analysis of the market based on the indication. This includes cervical cancer, prostate cancer, and others.

Cervical cancer is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV). Vaccines targeting HPV have been successful in preventing cervical cancer. The market for cervical cancer vaccines is driven by the increasing awareness about the role of HPV in cervical cancer development, along with the implementation of national vaccination programs. Vaccines, such as Gardasil and Cervarix, have been developed specifically to prevent HPV infection and subsequent development of cervical cancer. These vaccines have shown remarkable efficacy in preventing HPV infections and reducing the incidence of cervical precancerous lesions. The market segment for cervical cancer vaccines is expected to grow as vaccination rates improve and more countries include HPV vaccination in their immunization programs.

Prostate cancer is the most common cancer among men, and the demand for effective treatment options is high. Vaccines targeting prostate cancer work by stimulating the immune system to recognize and attack prostate cancer cells. Sipuleucel-T (Provenge) is an example of an FDA-approved therapeutic vaccine for advanced prostate cancer. It is designed to boost the patient's immune response against prostate cancer cells. The market for prostate cancer vaccines is driven by the need for innovative treatment options that can improve overall survival and quality of life for patients. Additionally, the rising prevalence of prostate cancer, especially in aging population, contributes to the market growth. Moreover, ongoing research and clinical trials developing new prostate cancer vaccines, is further enhancing the potential of this market segment.

Breakup by End User:

Pediatrics

Adults

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes pediatrics and adults.

Pediatric patients, including infants, children, and adolescents, represent a crucial target population for cancer vaccines. Vaccination in pediatrics aims to prevent cancers associated with infectious agents, such as cervical cancer caused by HPV or liver cancer caused by HBV. Vaccinating children and adolescents against these infections can provide long-term protection and reduce the risk of developing associated cancers in adulthood. Government immunization programs and initiatives aimed at promoting pediatric vaccination have been instrumental in driving the market growth. Other than this, the demand for pediatric cancer vaccines is expected to increase with the increasing awareness about the benefits of early prevention and vaccination.

While pediatric vaccination focuses on preventing cancers in early stages of life, adult vaccination targets both preventive and therapeutic purposes. In terms of prevention, adult cancer vaccines primarily aim to protect against infectious agents that contribute to certain cancers, such as HPV-associated cancers, HBV-related liver cancer, and human immunodeficiency virus (HIV)-associated cancers. Additionally, therapeutic vaccines targeting specific antigens expressed by cancer cells are being developed for adult patients. These therapeutic vaccines are designed to stimulate the immune system and enhance the body's ability to recognize and attack cancer cells. The market for adult cancer vaccines is driven by the growing emphasis on preventive healthcare, increasing awareness regarding vaccination benefits in adults, and advancements in therapeutic vaccine research and development.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-developed healthcare infrastructure and advanced research capabilities. The region is home to numerous leading pharmaceutical and biotechnology companies, academic institutions, and research centers specializing in cancer research. This robust ecosystem fosters innovation, enabling the development and commercialization of cutting-edge cancer vaccines. The presence of well-established regulatory frameworks and stringent quality standards further supports the growth of the market in North America. Additionally, there is a high prevalence of cancer in this region, which is accelerating the adoption of effective treatment options, including cancer vaccines. The region experiences a significant burden of various cancers, such as lung, breast, prostate, and colorectal cancers. This increased incidence of cancer creates a substantial market opportunity for cancer vaccines as patients and healthcare providers seek novel therapies for prevention, treatment, and improved patient outcomes. Other than this, North America has a strong emphasis on preventive healthcare and vaccination programs. The region's healthcare systems prioritize disease prevention and public health initiatives, including immunization campaigns. Moreover, vaccination against infectious agents associated with certain cancers, such as HPV and HBV, is actively promoted, leading to a higher uptake of preventive cancer vaccines.

Competitive Landscape:

Key players are actively investing in research and development to advance the development of cancer vaccines. They are focused on identifying novel tumor antigens, optimizing vaccine formulations, and exploring innovative delivery systems. Healthcare companies are conducting extensive preclinical and clinical trials to demonstrate the safety, efficacy, and potential of their cancer vaccine candidates. These trials involve collaboration with healthcare institutions and involve a large patient population. By supervising rigorous clinical trials, they are gathering valuable data on the performance of their vaccines, demonstrating their efficacy, and paving the way for regulatory approvals and market entry. Other than this, key players are actively working on expanding market access for cancer vaccines. They are involved in obtaining regulatory approvals in various countries, ensuring manufacturing scalability, and establishing distribution networks. Companies are also focused on educating healthcare providers, patients, and the general public about the benefits of cancer vaccines. Marketing and promotional activities are carried out to create awareness, enhance adoption rates, and drive market growth. Besides this, they continue to invest in their product pipelines and drive innovation in the market by constantly exploring new vaccine candidates, improving existing formulations, and discovering novel approaches to enhance immune responses.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Anixa Biosciences Inc.

Dendreon Pharmaceuticals LLC

Dynavax Technologies Corporation

GSK plc

Merck & Co. Inc.

Moderna Inc.

OSE Immunotherapeutics

Providence Therapeutics

Sanofi S.A.

UbiVac Inc.

Vaccitech PLC

Recent Developments:

GSK Plc is actively involved in the development of cancer vaccines as part of its commitment to advancing healthcare. In 2022, the company invested £5.5 billion in R&D, 9% AER more than 2021, to enhance its pipeline of vaccines and medicines.

In October 2023, Merck announced that it will be jointly developing and commercializing mRNA-4157/V940 with Moderna. Moderna Inc. has been making recent developments in the cancer vaccines industry by working on mRNA vaccines for cancer treatment.

In 2023, OSE Immunotherapeutics is developing a cancer vaccine called Tedopi, which is the first cancer vaccine to demonstrate clinically meaningful efficacy results, along with a better safety and quality of life profile. It is currently in late-stage clinical development for lung cancer. The Phase 3 results of Tedopi have shown promising outcomes in the field of Immuno-Oncology. Additionally, a new patent has been granted to protect Tedopi as a therapeutic cancer vaccine.

Key Questions Answered in This Report

1. How big is the global cancer vaccines market?
2. What is the expected growth rate of the global cancer vaccines market during 2024-2032?
3. What are the key factors driving the global cancer vaccines market?
4. What has been the impact of COVID-19 on the global cancer vaccines market?
5. What is the breakup of the global cancer vaccines market based on the type?
6. What is the breakup of the global cancer vaccines market based on the technology?
7. What are the key regions in the global cancer vaccines market?
8. Who are the key players/companies in the global cancer vaccines market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cancer Vaccines Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Preventive Cancer Vaccines
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Therapeutic Cancer Vaccines
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Technology

7.1 Dendritic Cells Cancer Vaccines
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Recombinant Cancer Vaccines
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Antigen/Adjuvant Cancer Vaccines
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Viral Vector and DNA Cancer Vaccines
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Whole-cell Cancer Vaccines
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Indication

8.1 Cervical Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Prostate Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by End User

9.1 Pediatrics
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Adults
- 9.2.1 Market Trends
- 9.2.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Anixa Biosciences Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Dendreon Pharmaceuticals LLC
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
- 15.3.3 Dynavax Technologies Corporation
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
- 15.3.4 GSK plc
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Merck & Co. Inc.
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Moderna Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
- 15.3.7 OSE Immunotherapeutics
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
- 15.3.8 Providence Therapeutics
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
- 15.3.9 Sanofi S.A.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 UbiVac Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
- 15.3.11 Vaccitech plc
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials

簡介目錄圖表

List of Figures

Figure 1: Global: Cancer Vaccines Market: Major Drivers and Challenges
Figure 2: Global: Cancer Vaccines Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Cancer Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Cancer Vaccines Market: Breakup by Type (in %), 2023
Figure 5: Global: Cancer Vaccines Market: Breakup by Technology (in %), 2023
Figure 6: Global: Cancer Vaccines Market: Breakup by Indication (in %), 2023
Figure 7: Global: Cancer Vaccines Market: Breakup by End User (in %), 2023
Figure 8: Global: Cancer Vaccines Market: Breakup by Region (in %), 2023
Figure 9: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 10: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 11: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Cancer Vaccines (Cervical Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Cancer Vaccines (Cervical Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Cancer Vaccines (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Cancer Vaccines (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Cancer Vaccines (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Cancer Vaccines (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Cancer Vaccines (Pediatrics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Cancer Vaccines (Pediatrics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Cancer Vaccines (Adults) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Cancer Vaccines (Adults) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: North America: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: North America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: United States: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: United States: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Canada: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: Canada: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Asia-Pacific: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Asia-Pacific: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: China: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: China: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: Japan: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: Japan: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: India: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: India: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: South Korea: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: South Korea: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Australia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Australia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Indonesia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Indonesia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: Europe: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: Europe: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Germany: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Germany: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: France: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: France: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: United Kingdom: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: United Kingdom: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Italy: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Italy: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: Spain: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: Spain: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: Russia: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: Russia: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Latin America: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Latin America: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Brazil: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Brazil: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Mexico: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Mexico: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Others: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 78: Others: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 79: Middle East and Africa: Cancer Vaccines Market: Sales Value (in Million US$), 2018 & 2023
Figure 80: Middle East and Africa: Cancer Vaccines Market: Breakup by Country (in %), 2023
Figure 81: Middle East and Africa: Cancer Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Global: Cancer Vaccines Industry: SWOT Analysis
Figure 83: Global: Cancer Vaccines Industry: Value Chain Analysis
Figure 84: Global: Cancer Vaccines Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cancer Vaccines Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Cancer Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Cancer Vaccines Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 4: Global: Cancer Vaccines Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 5: Global: Cancer Vaccines Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 6: Global: Cancer Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 7: Global: Cancer Vaccines Market: Competitive Structure
Table 8: Global: Cancer Vaccines Market: Key Players

02-2729-4219

+886-2-2729-4219